Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects

Background Macitentanis a clinically approved endothelin receptor antagonistfor the treatment of pulmonary arterial hypertension (PAH). Increasing use of combination drugtherapy in PAH means that it is important to recognize potential drug–drug interactions(DDIs) that could affect the efficacy and safety of macitentanin patients with PAH.